SCHEMBL6293728

SCHEMBL6293728

CCCC1=C(C(=O)OCC)C(c2cccc(C)c2Cl)c2c[nH]nc2N1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 3/20 0.44
KDM4E B2RXH2 3/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
ABCB11 O95342 3/20 0.44
ADORA3 P0DMS8 3/20 0.44
TBXA2R P21731 3/20 0.44
ADRA1A P35348 3/20 0.44
SLC6A3 Q01959 3/20 0.44
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2C19 P33261 2/20 0.44
HIF1A Q16665 2/20 0.44
HSD17B10 Q99714 2/20 0.44
ALDH1A1 P00352 2/20 0.44
ABCB1 P08183 2/20 0.44
ADRB3 P13945 2/20 0.44
OPRK1 P41145 2/20 0.44
SCN5A Q14524 2/20 0.44
TSHR P16473 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6293510 0.92 CYP2C9 (0.54) CYP2C9KDM4EMEN1KMT2AABCB11
SCHEMBL6296991 0.90 NR3C2 (0.45) KDM4EMEN1KMT2AADORA3HSD17B10
SCHEMBL6292579 0.88 CYP2C9 (0.44) CYP2C9KDM4EMEN1KMT2AABCB11
SCHEMBL6292289 0.88 TBXA2R (0.48) CYP2C9KDM4EMEN1KMT2AABCB11
SCHEMBL6296723 0.88 NR3C2 (0.45) CYP2C9KDM4EMEN1KMT2AABCB11
SCHEMBL6293480 0.88 CACNA1C (0.42) CYP2C9KDM4EMEN1KMT2AABCB11
SCHEMBL6296486 0.87 NR3C2 (0.40) CYP2C9KDM4EMEN1KMT2AABCB11
SCHEMBL6296626 0.87 CACNA1C (0.51) CYP2C9KDM4EMEN1KMT2AABCB11
SCHEMBL6292296 0.86 CYP2C9 (0.43) CYP2C9KDM4EMEN1KMT2AABCB11
SCHEMBL8342908 0.85 NR3C2 (0.41) CYP2C9KDM4EMEN1KMT2AABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6977262-B2 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2005-12-20 US disclosed
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-03-18 US disclosed
WO-2002062795-A9 DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040052822-A1 Dihydropyrazolopyridine compounds and pharmaceutical use thereof GSK3B, GSK3A, PYGB CYP2C9 1705/4885KDM4E 1992/4885MEN1 3826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.